Skip to main content
Smart Investors Daily
NA

NASDAQ · NAMS

NewAmsterdam Pharma Company N.V.

Healthcare · Biotechnology

$18.41

Down-$1.10 (-5.64%)

Updated Nov 22, 2026, 2:35 PM

SID Score

3.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.1B
P/E ratio
-19.49
Dividend yield
0.00%
52-week range
$17.90 – $42.21
Volume
1.75M
Avg. volume
1.15M

Price performance · NAMS

NAMS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

NAMS closed at $18.41 after 20 trading sessions, down 5.73% for the selected period.

Last close
$18.41
Period change
-5.73%
Period low
$18.41
Period high
$21.07
Daily close
View OHLC price history
NAMS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$19.21$19.78$18.285$18.411.75M
Nov 19, 2026$20.00$20.36$19.30$19.511.98M
Nov 18, 2026$19.28$20.10$19.2602$19.741.8M
Nov 17, 2026$19.45$20.2999$18.90$19.391.36M
Nov 16, 2026$19.94$20.54$19.45$19.461.68M
Nov 13, 2026$19.93$20.62$19.48$20.141.67M
Nov 12, 2026$20.76$20.76$19.31$19.972.28M
Nov 11, 2026$19.52$20.82$19.30$20.722.62M
Nov 10, 2026$18.97$20.04$18.90$19.182.36M
Nov 9, 2026$19.08$19.38$17.90$19.002.76M
Nov 6, 2026$19.10$19.385$18.50$18.901.71M
Nov 5, 2026$20.77$20.77$18.86$18.891.56M
Nov 4, 2026$22.26$22.26$19.81$20.931.89M
Nov 3, 2026$19.74$20.46$19.59$19.902.07M
Nov 2, 2026$20.23$20.955$19.545$19.562.01M
Oct 30, 2026$20.60$20.94$19.78$20.061.14M
Oct 29, 2026$21.45$21.725$20.55$20.761.03M
Oct 28, 2026$20.59$21.115$20.09$21.071.45M
Oct 27, 2026$19.50$20.60$19.32$20.501.97M
Oct 26, 2026$19.68$19.98$19.265$19.531.56M

Latest NAMS news

The latest Smart Investors Daily articles mentioning NAMS.

NAMS research

Overview

Company profile and research snapshot.

Company profile

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$44.67
Implied upside
—
Analysts
—
NAMS recent ratings
DateFirmRatingTarget
Nov 11, 2026Cantor FitzgeraldOverweight—
Nov 5, 2026NeedhamBuy—
Oct 5, 2026RBC CapitalOutperform—
Sep 8, 2026HC Wainwright & Co.Buy—
Aug 6, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.